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Abstract Human metapneumovirus (hMPV) worldwide
causes respiratory tract infections with features similar to
those of RSV infection. We describe features of hMPV
infections in children and compare some of the character-
istics with those of RSV infections. From October 2004 to
February 2006, 75 patients, 34 hospitalized and 41 out-
patients, were diagnosed with hMPV infections by multi-
plex PCR applied to nasopharyngeal specimens. While
hMPV was found rarely in the early phase of the study, a
significant increase occurred in the second winter of the
study period. Patients with hMPV infections were older
than those with RSV infection; clinical characteristics were
similar as was the rate of serious disease among hospital-
ized patients (intensive care treatment: 18% versus 8%). In
conclusion, hMPV leads to endemic and epidemic respira-
tory disease with features similar to those of RSV and
should be considered in the differential diagnosis of upper
and lower respiratory tract disease.
Keywords Human metapneumovirus (hMPV) .
Respiratory tract infection (RTI) . Children
Introduction
Human metapneumovirus (hMPV) is a recently discovered
paramyxovirus that is associated with acute respiratory tract
infections (RTIs) in children and adults. Since its first
description in 2001 [36], the virus has been further
identified in patients with RTIs from all continents [1, 3,
8, 9, 14, 15, 19, 21, 22, 27–34, 41]. Seroprevalence studies
in the Netherlands [36], Israel [44] and Japan [11] have
shown that by the age of 5 to 10 years, seropositivity
reaches virtually 100%. Longitudinal surveys have indicat-
ed that hMPV has a seasonal distribution similar to
respiratory syncytial virus (RSV) and influenza viruses
[15, 18, 34, 42].
In October 2004, a reverse-transcriptase-polymerase
chain-reaction (RT-PCR) assay was added to the panels of
multiplex PCR in our laboratory to test nasopharyngeal
aspirates from in- and outpatients with RTIs for the
presence of respiratory pathogens [25]. Whereas only a
small number of samples tested positive for hMPV in the
first winter season after its introduction, we observed a
remarkable increase of hMPV infections during the follow-
ing winter season (October 2005 to February 2006). Here
we present demographic and clinical features of hMPV
infections in children that, to the best of our knowledge, is
the first such report from Switzerland. Further, we compare
some of the observed epidemiologic characteristics with
those of RSV infections that were diagnosed during the
same time period.
Materials and methods
Study subjects
Our microbiological laboratories provide a broad range of
diagnostic services for in- and outpatients of our children’s
hospital. In addition, several pediatricians in the close
vicinity take advantage of our services. From 11 October
2004 onwards, a RT-PCR for detection of hMPV was
performed in nasopharyngeal aspirates (NP) sent to our
laboratory in addition to the use of a previously established
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multiplex PCR for detection of RSV, parainfluenza virus types
1 and 3, influenza A and B, and adenovirus. All assays had
undergone comprehensive in-house evaluation before their
introduction. NP were obtained from hospitalized patients as
well as outpatients with acute RTIs according to standard
clinical care in our institution and collaborating private
pediatric offices. Laboratory personnel were unaware of any
clinical information on the respective patients.
Clinical information (based on a standardized question-
naire) and laboratory data were abstracted from the medical
records of hospitalized patients retrospectively in March
2006. For outpatients, questionnaires were sent to the
pediatrician or practitioner who had collected the NP speci-
mens. Specifically, demographic characteristics (age, gender,
prematurity and underlying chronic diseases), onset of
symptoms, duration of illness, clinical signs and symptoms,
medication and the final clinical diagnosis were collected.
The study protocol was approved by the University of
Basel Medical Faculty’s ethical commission. Informed
consent was obtained from the patients’ parents.
Case definition
Upper respiratory tract infection (URTI) was diagnosed in
the presence of characteristic signs or symptoms of rhinitis,
pharyngitis, conjunctivitis or acute otitis media. Children
with further signs or symptoms of pneumonia, bronchitis or
bronchiolitis were diagnosed to have lower respiratory tract
infection (LRTI).
Laboratory investigations
NP specimens were placed into transport medium (0.9%
sterile sodium-chloride solution), sent to the laboratory
immediately and stored at 4°C until PCR was performed
(within 48 h). Nucleic acid for RT-PCR was extracted from
a 140-μl nasopharyngeal sample with a commercial kit
(QIAamp Viral RNA mini Kit, QIAGEN AG, Basel,
Switzerland) according to the manufacturer’s instructions.
RT-PCR for hMPV was performed by use of a one-tube
reaction (Titan One Tube RT-PCR System, Roche Diag-
nostics GmbH Mannheim, Germany) according to the
manufacturer’s instructions. Briefly, a primer pair compris-
ing hMPV L-L Hex labeled (5′ CAT GCC CAC TAT AAA
AGG TCA G 3′) and hMPV L-R1 (5′ CAC CCC AGT CTT
TCT TGA AA 3′), amplifying a fragment of 170 bp in the
polymerase gene as described by van den Hoogen et al.
[37], was used. In addition, a second primer pair hMPV N-
L1 (5′ GCA TGC TAT ATT AAA AGA GTC TCA 3′) and
hMPV N-R FAM labeled (5′ ATC TCA GCA GCA TAT
TTG TA 3′) was used for amplification of a highly
conserved fragment of 157 bp in the nucleoprotein gene.
These primers were slightly modified based on those
previously described by Maertzdorf at al. [24]. PCR
products then were subjected to capillary electrophoresis
on an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems). Amplified fragments were identified accord-
ing to fluorescent color (corresponding to the labeled
primers) and fragment size within the electropherogram.
As a positive control, RNA of hMPV (subtype A2,
according to strain Canada 97/83) was used in every run of
PCR (kindly provided by Prof. Dr. D. Neumann-Haefelin,
Department of Medical Microbiology and Hygiene, Uni-
versity of Freiburg, Germany). The hMPV was considered
present if either hMPV N gene or hMPV L gene or both
could be detected.
The two hMPV RT-PCRs were integrated in the existing
in-house RT-multiplex PCR as follows: primers for the
hMPV N gene were combined with those for RSV,
influenza viruses A and B (block 1), and primers for
HMPV L gene were combined with those for adenoviruses
and parainfluenza type 1 and type 3 viruses (block 2) [6,
13, 20, 26, 38]. RNA of RNA viruses was transcribed to
cDNA before PCR was performed. PCR techniques were
not changed over the course of the study period.
When specifically ordered by the physician, a separate
PCR for the detection of Mycoplasma pneumoniae was also
performed as described previously by Ieven et al. [17].
Statistical methods
Data were entered into a database, and statistical analyses
were performed using SPSS (version 13.0, SPSS, Inc.,
Chicago, IL). Clinical characteristics and laboratory varia-
bles were compared by Student’s t-test, Mann-Whitney U
test, Fisher’s exact test, chi squared test or odds ratio
analysis as appropriate. A two-sided P value of <0.05 was
considered significant.
Results
Epidemiological characteristics
During the two winter seasons from 11 October 2004 to 28
February 2006, a total of 2,582 NP specimens were
received by our laboratory for PCR tests to detect
respiratory pathogens. Based on the physicians’ orders for
the detection of viruses from multiplex-PCR blocks 1 and
2, 1,500 (58%) of 2,582 specimens were tested for hMPV:
1,499 (58%) for the hMPV N gene and 1,181 (46%) for the
hMPV L gene (1,180 for N gene and L gene, 319 for N
gene only and 1 for L gene only). Infection with hMPV was
detected in 75 (5%) of 1,500 children, where 74 (4.9%) of
1,499 tested specimens were positive for hMPV N gene and
29 (2.5%) of 1,181 for hMPV L gene (p<0.01). Thus, PCR
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for L gene only contributed a single case that would not
have been identified by use of N gene PCR primers.
Informed consent and clinical data could be obtained
from the parents of 74 (99%) of 75 children infected with
hMPV. Whereas only 3 of 691 (0.4%) NP specimens tested
for hMPV in the first winter season of this study (October
2004 to March 2005) were positive, the proportion
increased to 3.2% between April and September 2005 (8
of 248 NP specimens positive), and further increased
during the following winter season to 11% (64 hMPV
positives among 560 NP specimens). The increase in the
proportion of hMPV started in October 2006, reached its
peak in December and gradually declined over the next
2 months (Fig. 1).
RSV was detected in 294 (19.5%) of 1,505 specimens
during the same study period with a higher prevalence during
the winter season 2004/2005 compared to winter season 2005/
2006 (Fig. 1). Overall, hMPVand RSV were detected in 14%
and 54%, respectively, of all 520 samples positive for ≥1
respiratory virus by PCR during the study period (Fig. 2).
Five (7%) of the 75 hMPV-infected patients were
documented to be coinfected with other respiratory patho-
gens: one (1%) with RSV and four (11%) with M.
pneumoniae (of 36 NP specimens tested for both M.
pneumoniae and hMPV).
Clinical characteristics
Patients with hMPV infections were significantly older (mean
age 32 months, median 17, interquartile range: 7–44) than
RSV-positive patients (mean age 16 months, median 9,
interquartile range: 3–17; p=0.001). Specifically, 29 (39%)
of 75 hMPV infections occurred in infants compared with 183
(62%) of 294 RSV infections (p<0.001).
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Fig. 2 Percentage of nasopharyngeal aspirates from patients with respiratory tract infections that tested positive for RSV and hMPV by study
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Male predominance was more pronounced among
children with hMPV infections compared to those with
RSV infections (63% versus 55%), but this difference was
not significant.
Of 75 hMPV-positive children, 34 (45%) were hospital-
ized (RSV: 158 of 294; 54%; p=0.19), and 6 (18%) of them
required intensive-care treatment because of imminent
respiratory failure (RSV: 13 of 158; 8%; p=0.095). The
remaining 41 patients were treated as outpatients. Of the six
patients requiring intensive care, two had co-infections of
hMPVand a further respiratory pathogen: one 17.8-year-old
girl with trisomy 21, congenital heart disease and infection-
associated hepatitis and myocarditis was co-infected with
M. pneumoniae; she needed mechanical ventilation for
8 days and supportive oxygen therapy for 24 consecutive
days. Furthermore, a 1-month-old boy was co-infected with
RSV and also recovered on intensive care treatment.
A summary of clinical characteristics of hMPV infec-
tions and a comparison between hospitalized children and
outpatients are demonstrated in Table 1. Mean duration of
hospitalization for community-acquired hMPV infections
was 6.6±8.9 days (median 4, interquartile range 2–6). One
patient acquired a nosocomial hMPV infection. He had a
VACTERL association and developed respiratory symp-
toms on day 46 from which he recovered. Subsequently,
however, he also acquired parainfluenza virus infection and
finally died on day 106 due to his underlying condition. No
other deaths in hMPV-positive patients occurred.
Dyspnea, need for oxygen supplementation and feeding
difficulties or loss of appetite were the only characteristics
that were more frequent among hospitalized children who
also tended to be younger than outpatients. Most of the
patients with hMPV infections had LRTI (n=57; 77%), and
this was true for both in- and outpatients. Age distribution
Table 1 Comparison of clinical characteristics of hospitalized and outpatients with hMPV infections
Clinical characteristics Totala
n=75 (%)
Outpatientsa
n=41 (%)
Hospitalized patients;
n=34 (%)
P valueb OR (95% CI)
Age in months (mean±SD) 31.7±38.9 35.6±38.7 27±39.3 Not applicable
Male gender 47/75 (63) 26/41 (63) 21/34 (62) 1.07 (0.42–2.75)
Prematurity 8/61c (13) 4/27c (15) 4/34 (12) 0.77 (0.17–3.40)
Body temperature 37.1–38.4°C 17/74 (23) 9/40 (23) 8/34 (24) Not applicable
≥38.5–38.9°C 14/74 (19) 12/40 (30) 2/34 (6) Not applicable
≥39°C 43/74 (58) 19/40 (48) 24/34 (71) Not applicable
Cough 73/74 (99) 39/40 (98) 34/34 (100) Not applicable
Dyspnea 34/74 (46) 11/40 (28) 23/34 (68) 0.001 5.51 (2.03–14.97)
Wheezing 34/74 (46) 15/40 (36) 23/34 (68) 2.11 (0.83–5.36)
URTI 65/74 (88) 33/40 (83) 32/34 (94) 3.39 (0.66–17.58)
- Conjunctivitis 7/74 (9) 2/40 (5) 5/34 (15) 3.28 (0.59–18.10)
- Rhinitis 58/74 (78) 29/40 (73) 29/34 (85) 2.20 (0.68–7.13)
- Pharyngitis 34/74 (46) 16/40 (40) 18/34 (53) 1.69 (0.67–4.25)
- AOM 10/74 (14) 7/40 (18) 3/34 (9) 0.46 (0.10–1.92)
LRTI d 57/74 (77) 30/40 (75) 27/34 (79) 1.29 (0.43–3.85)
- Pneumonia 25/74 (34) 10/40 (25) 15/34 (44) 2.37 (0.88–6.34)
- Bronchitis 34/74 (46) 21/40 (51) 13/34 (38) 0.56 (0.22–1.42)
- Bronchiolitis 13/74 (18) 5/40 (13) 8/34 (24) 2.15 (0.63–7.35)
- Croup 5/74 (8) 2/40 (5) 3/34 (9) 1.84 (0.29–11.71)
Exanthema 8/74 (11) 3/40 (8) 5/34 (15) 2.13 (0.47–9.64)
Feeding difficulties/loss of appetite 26/74 (35) 9/40 (23) 17/34 (50) 0.014 3.44 (1.26–9.38)
Vomiting 25/74 (34) 13/40 (33) 12/34 (35) 1.13 (0.43–2.97)
Concomitant diarrhea 19/74 (26) 14/40 (35) 5/34 (15) 0.046 0.32 (0.10–1.01)
Treatment
- Antibiotics 38/74 (51) 19/40 (48) 19/34 (56) 1.40 (0.56–3.51)
- Oral steroids 9/74 (12) 1/40 (3) 8/34 (24) 0.017 12.0 (1.42–101.7)
- Inhalative therapy 27/74 (36) 7/40 (18) 20/34 (59) 0.001 6.73 (2.32–19.5)
- Bronchodilatator 20/74 (27) 5/40 (13) 15/34 (44) 0.003 Not applicable
- Bronchodilatator/steroids 7/74 (9) 2/40 (5) 5/34 (15) 0.003 Not applicable
- Oxygen therapy 13/74 (18) 0/40 (0) 13/34 (38) <0.0001 Not applicable
a Data on most characteristics are missing for one outpatient due to lack of parental consent
b If <0.05
c Data on 14 patients missing due to lack of documentation (n=13) or lack of parental consent (n=1)
dMore than one diagnosis of LRTI was made in some patients
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was similar between patients with LRTI and those with URTI
only (data not shown). Interestingly, though, children with
pneumonia were significantly older than those with other
manifestations of respiratory tract disease (mean 46.9±
47.2 months and 24.5±32.2 months, respectively; p=0.04).
Three children-17, 19 and 36 months old-presented with
a febrile convulsion, and one further patient experienced a
relapse of nephrotic syndrom while suffering from hMPV
infection. Twenty-two (30%) of 74 hMPV infected children
had various forms of underlying chronic disease and 15
(68%) of them were hospitalized compared with 19 (37%)
of 52 primary healthy children (p=0.03).
Discussion
Human metapneumovirus, a member of the Paramyxo-
viridiae family, is a single-stranded negative-sense RNA
virus that was first described by Dutch investigators, who
isolated the virus from young children with RTI [36]. Here
we report the first description of a large number of hMPV
infections in children in Switzerland and provide a detailed
description of epidemiological and clinical characteristics.
During the 2-year study period the detection rate steadily
increased from 0.4% (months 1–6) to 3.2% (months 7–12)
and finally reached a proportion as high as 11% of tested NP
samples being hMPV positive (months 13–17). Whether this
represents a pattern of biannual major epidemics similar to
those observed with RSV remains to be seen [2, 10, 39].
Previous reports of hMPV infections from various countries
have described a characteristic seasonality with peaks during
the cold seasons [9, 15, 18, 34, 42], but none of these studies
was performed over a prolonged period of time. Similarly,
we observed an impressive peak during winter 2005/2006,
and we will continue our observations in order to better
define the seasonality of hMPV infections in the future.
The overall detection rate for hMPV in this study was 5%,
which is in the lower range of rates that have been detected
among children with acute RTIs in previous investigations
from Europe, North and South America, South Africa,
Australia and Asia, most of them restricted to hospitalized
patients, i.e., 5 to 16% [8, 12, 19, 21, 27, 30, 31, 42]. Studies
with detection rates in the upper range usually were restricted
to winter seasons when peaks of infections occur. In contrast,
those with rates in the lower range frequently also covered
summer months (which necessarily leads to a lower
percentage of detection), like our study, which was uninter-
rupted for 17 consecutive months.
Although no viral cultures were performed to assess the
overall sensitivity of PCR tests in this study, PCR based on
N gene primers was more sensitive than PCR based on L
gene primers. In a comparative evaluation of real-time PCR
assays for the detection of hMPV, N and L gene primers
were shown to be most suitable, and sensitivity of N gene
primers was superior to that of L gene primers, which is in
accordance with our findings [7]. Given the fact that the
additional use of L gene primers contributed only minimal-
ly to the overall sensitivity of PCR for hMPV in our study,
it appears that the use of N gene primers alone is sufficient.
The presenting signs and symptoms of hMPV infection
are reminiscent of those associated with RSV [25].
However, hMPV-infected patients were significantly older
than RSV-infected patients in this study, which is consistent
with findings in the literature [30, 37, 42, 43]. Moreover,
despite the fact that both viruses mainly circulate during the
winter season, we identified only a single patient with dual
hMPV and RSV infection. This underlines the notion that
both viruses independently cause similar infections [37].
When comparing the clinical presentation of hospitalized
hMPV-infected patients with those of outpatients, hospital-
ized patients tended to be younger and more frequently
suffered from dyspnea and feeding difficulties or loss of
appetite. Interestingly, 77% of hMPV-infected patients
suffered from LRTI. This was not different between
hospitalized and outpatients, which may be explained by
the retrospective design of our study where outpatients with
more serious disease probably had been selected for
diagnostic testing. However, wheezing tended to be more
frequent among hospitalized children (68%). Consequently,
38% of them needed oxygen supplementation (compared to
none of the outpatients), and steroids and bronchodilators
were also used more frequently in hospitalized children
than in outpatients. Although this was a retrospective
analysis open to the introduction of bias, these differences
are quite plausible.
Approximately 50% of patients received antibiotics
during some stage of their illness, and this rate appears to
be high. However, in most instances antibiotic treatment
was prompted by concomitant pneumonia or acute otitis
media where secondary bacterial infections apparently were
suspected and/or the presence of hMPV infection was not
yet known. Similarly, 60% of hospitalized children with
hMPV infection were treated with antibiotics in the
Netherlands, a country with a restrictive policy for the use
of antibiotics like in Switzerland [37].
Thirty percent of hMPV-infected patients had chronic
underlying diseases, and 11% had a history of prematurity,
similar to previous observations [4, 12, 37, 40]. This may be
an indication for increased susceptibility in these hosts and/
or an artifact explained by the fact that physicians are more
likely to order diagnostic tests in these high-risk patients.
There are conflicting results concerning whether dual
infections by hMPV and other respiratory tract viruses,
mainly RSV, are associated with a more severe disease than
that observed with hMPV as the single etiological cause of
disease. Semple et al. reported a tenfold increase in the
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relative risk of admission to a pediatric intensive-care unit
for mechanical ventilation due to severe bronchiolitis in
patients with dual infection with hMPV and RSV [35].
Similarly, dual infections with hMPV and RSV were found
in 70% of infants with severe bronchiolitis admitted to a
pediatric intensive-care unit for mechanical ventilation [16].
This is further supported by other recent data mainly in
children less than 3 years of age [14, 22]. In contrast, other
studies have failed to demonstrate more serious disease
with dual infections [5, 15, 23, 40, 41, 43]. Although we
only found a single patient with hMPV and RSV co-
infection, this infant required intensive care treatment.
Larger studies are needed to elucidate whether-and if so
by which mechanisms-hMPV and RSV co-infection leads
to a more serious course of respiratory disease or not.
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